A Study to Evaluate the Efficacy and Safety of Sirukumab in Confirmed Severe or Critical Confirmed Coronavirus Disease (COVID)-19
Clinical trial NCT04380961 · COMPLETED
Trial details
- NCT number
- NCT04380961
- Sponsor
- Janssen Pharmaceutica N.V., Belgium
- Status
- COMPLETED
- Phase
- Phase 2
- Study type
- INTERVENTIONAL
- Start date
- 2020-04-24
- Primary completion
- 2021-04-09
- Enrollment
- 212
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.